On June 5, PharmJet AnKang-B (Yaojie Ankang-B) declined 5.41% in regular trading, trading at HK$32.14 per share, with trading volume of approximately HK$73.33 million.

On the news front, the company recently presented key Phase II clinical data for its core product Tinengotinib at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The poster presentation disclosed efficacy and safety results of Tinengotinib monotherapy in Chinese advanced cholangiocarcinoma patients who had progressed on prior FGFR inhibitor treatment. As of the data cutoff date, 50 patients were enrolled, with a median follow-up of 12 months. Per blinded independent central review (BICR), the objective response rate (ORR) was 28.0%, with 14 patients achieving confirmed partial response. While the data demonstrated durable anti-tumor activity and a manageable safety profile, the market reaction suggests investors may have anticipated stronger results.

Additionally, the company recently completed an H-share placement of 3,836,000 shares at HK$40.83 per share, and was selected for inclusion in the HKEX Tech 100 Index effective June 15.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)